Publications (1)0 Total impact
-
A.F.G. Antonis,
C.J.M. Bruschke,
P Rueda,
L Maranga,
J. Casal,
C Vela,
L.A.T. Hilgers, P.B.G.M. Belt,
K. Weerdmeester,
M.J. Carrondo,
J.P.M. Langeveld
[show abstract]
[hide abstract]
ABSTRACT: A novel vaccine against porcine parvovirus (PPV), composed of recombinant virus-like particles (PPV-VLPs) produced with the baculovirus expression vector system (BEVS) at industrial scale, was tested for its immunogenicity and protective potency. A formulation of submicrogram amounts of PPV-VLPs in a water-in-mineral oil adjuvant evoked high serum antibody titres in both guinea pigs, used as reference model, and target species, pigs. A single immunisation with 0.7 ¿g of this antigen yielded complete foetal protection against PPV infection after challenge with a virulent strain of this virus. Furthermore, also in the presence of mild adjuvants the protective action of these PPV-VLPs is excellent. This recombinant subunit vaccine overcomes some of the drawbacks of classical PPV vaccines
Vaccine 24 (2006) 26.
